Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease

European Journal of Immunology

Volumn 44, Issue 11, 2014, Pages 3201-3205

  Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cancer; Paraneoplastic neurological disease; Shared antigens; T cells

Indexed keywords

AUTOANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANIMAL; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MOUSE; NEOPLASM; NERVE CELL; PARANEOPLASTIC NEUROPATHY;

ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; EPITOPES; HUMANS; IMMUNE TOLERANCE; MICE; NEOPLASMS; NEURONS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84916925127     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445191     Document Type: Note

References (22)

1. Sharma, P., Wagner, K., Wolchok, J. D. and Allison, J. P., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011. 11: 805-812.
2. Mellman, I., Coukos, G. and Dranoff, G., Cancer immunotherapy comes of age. Nature 2011. 480: 480-489.
3. Robert, C., Thomas, L., Bondarenko, I. et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011. 364: 2517-2526.
4. Amos, S. M., Duong, C. P. M., Westwood, J., Ritchie, D. S., Junghans, R. P., Darcy, P. K. and Kershaw, M. H., Autoimmunity associated with immunotherapy of cancer. Blood 2011. 118: 499-509.
5. Darnell, R. B. and Posner, J. B., Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 2003. 349: 1543-1554.
6. Greenlee, J. E. and Brashear, H. R., Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann. Neurol. 1983. 14: 609-613.
7. Bashyam, H., Uncovering the dark side of TNF. J. Exp. Med. 2007. 204: 2013.
8. Feldmann, M. and Maini, R. N., Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J. Immunol. 2010. 185: 791-794.
9. Blachère, N. E., Orange, D. E., Santomasso, B. D., Doerner, J., Foo, P. K., Herre, M., Fak, J. et al., Brain antigen targeted in paraneoplastic neurologic disease limits neuronal autoimmunity but not cancer rejection by adoptively transferred T cell. Eur. J. Immunol. 2014. 44: 3240-3251.
10. Yang, Y. Y., Yin, G.L. and Darnell, R.B., The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc. Natl. Acad. Sci. USA 1998. 95: 13254-13259.
11. Steinman, L., Autoimmune Disease. Sci. Am. 1993. 269: 106-114.
12. Polans, A. S., Witkowska, D., Haley, T. L., Amundson, D., Baizer, L. and Adamus, G., Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc. Natl. Acad. Sci. USA 1995. 92: 9176-9180.
13. Matsubara, S., Yamaji, Y., Fujita, T., Kanayama, T., Yamadori, I., Sato, M., Fujita, J. et al., Cancer-associated retinopathy syndrome: a case of small cell lung cancer expressing recoverin immunoreactivity. Lung Cancer 1996. 14: 265-271.
14. Furneaux, H. M., Rosenblum, M. K., Dalmau, J., Wong, E., Woodruff, P., Graus, F. and Posner, J. B., Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N. Engl. J. Med. 1990. 322: 1844-1851.
15. Sakai, K., Mitchell, D. J., Tsukamoto, T. and Steinman, L., Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Ann. Neurol. 1990. 28: 692-698
16. Corradi, J. P., Yang, C., Darnell, J. C., Dalmau, J. and Darnell, R. B., A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J. Neurosci. 1997. 17: 1406-1415.
17. Dalmau, J., Tüzün, E., Wu, H. Y., Masjuan, J., Rossi, J. E., Voloschin, A., Baehring, J. M. et al., Ann. Neurol. 2007. 61: 25-36.
18. Sakai, K., Shirakawa, T., Kitagawa, Y., Li, Y. and Hirose, G., Induction of cytotoxic T lymphocytes specific for paraneoplastic cerebellar degeneration-associated antigen in vivo by DNA immunization. J. Autoimmun. 2001. 17: 297-302.
19. Steinman, L. and Zamvil, S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006. 60: 12-21.
20. Grifka-Walk, H. M., Lalor, S. J. and Segal, B. M., Highly polarized Th17 cells induce EAE via a T-bet independent mechanism. Eur. J. Immunol. 2013. 43: 2824-2831.
21. Roberts, W. K., Deluca, I. J., Thomas, A., Fak, J., Williams, T., Buckley, N., Dousmanis, A. G. et al., Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J. Clin. Invest. 2009. 119: 2042-2051.
22. Tarhini, A., Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013. 2013: Article ID 857519.